Biodexa Pharmaceuticals Plc (BDRX)

NASDAQ: BDRX · Real-Time Price · USD

1.320

-0.160 (-10.81%)

At close: Jul 31, 2026, 4:00 PM EDT

1.410

+0.090 (6.82%)

Pre-market: Aug 3, 2026, 5:35 AM EDT

Biodexa Pharmaceuticals Balance Sheet

Financials in millions GBP. Fiscal year is January - December.

Millions GBP. Fiscal year is Jan - Dec.

Assets

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	8.53	1.67	5.97	2.84	10.06
Cash & Short-Term Investments	8.53	1.67	5.97	2.84	10.06
Cash Growth	411.32%	-72.05%	110.54%	-71.80%	33.28%
Accounts Receivable	3.79	6.57	0.64	1.01	1.03
Other Current Assets	0.12	0.57	0.42	0.85	0.67
Total Current Assets	12.44	8.81	7.03	4.69	11.76
Net Property, Plant & Equipment	0.09	0.32	0.57	0.83	1.15
Other Intangible Assets	5.65	5.65	2.94	0.01	-
Total Assets	18.18	14.78	10.54	5.53	12.91

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	2.59	3.5	1.24	1.45	1.09
Current Portion of Long-Term Debt	0.06	0.61	0.17	0.16	0.15
Other Current Liabilities	3.48	0.92	4.16	0.29	0.6
Total Current Liabilities	6.13	5.03	5.57	1.9	1.84
Long-Term Debt	-	0.12	0.3	0.46	0.62
Other Long-Term Liabilities	0.65	1.31	-	-	-
Total Long-Term Liabilities	0.65	1.42	0.3	0.46	0.62
Total Liabilities	6.77	6.46	5.86	2.36	2.46

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	14.1	11.73	6.25	1.11	1.1
Additional Paid-in Capital	153.11	147.02	143.19	137.39	137.16
Accumulated Other Comprehensive Income	0	-	-	-	-
Retained Earnings	-155.81	-150.42	-144.77	-135.34	-127.8
Shareholders' Equity	11.41	8.32	4.68	3.16	10.45
Total Liabilities & Equity	18.18	14.78	10.54	5.53	12.91

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	0.06	0.73	0.46	0.62	0.77
Net Cash (Debt)	8.47	0.94	5.51	2.21	9.29
Net Cash Growth	799.47%	-82.89%	148.96%	-76.19%	27.52%
Net Cash Per Share	154444.59	190196.21	17435491.53	447611088.29	2306981779.54
Book Value	11.41	8.32	4.68	3.16	10.45
Book Value Per Share	207889.00	1680270.00	14810800.00	639849000.00	2595260000.00
Tangible Book Value	5.76	2.68	1.74	3.16	10.45
Tangible Book Value Per Share	104992.00	540302.00	5499450.00	638635000.00	2595260000.00

SEC Filings: 10-K · 10-Q